Surgical RF ablation of atrial fibrillation in patients undergoing mitral valve repair for barlow disease

Carlo Rostagno, G. Droandi, S. Gelsomino, E. Carone, G. F. Gensini, P. L. Stefàno

Research output: Contribution to journalArticle

Abstract

Objectives: At present, limited experience exists on the treatment of atrial fibrillation (AF) in patients undergoing mitral valve repair (MVR) for Barlow disease. The aim of this investigation was to prospectively evaluate the radiofrequency ablation of AF in patients undergoing MVR for severe regurgitation due to Barlow disease. Methods: From January 1, 2007 to December 31, 2010, out of 85 consecutive patients with Barlow disease, 27 with AF underwent RF ablation associated with MVR. They were examined every 4 months in the first year after surgery and thereafter twice yearly. Results: At follow-up, AF was observed in 4/25 (16.0%). NYHA (New York Heart Association) functional class improved significantly, with no patients in class III or IV (before surgery, 81.5% had been). Otherwise, among 58 patients in sinus rhythm, 6 (11%) developed AF during follow-up. No clinical or echocardiographic predictive factor was found in this subgroup. Conclusions: Results from our investigation suggest that radiofrequency ablation of AF in patients with Barlow disease undergoing MVR for severe regurgitation is effective and should be considered in every patient with Barlow disease and AF undergoing valve surgical repair.

Original languageEnglish
Pages (from-to)141-145
Number of pages5
JournalCardiology
Volume125
Issue number3
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Mitral Valve
Atrial Fibrillation
Surgical Instruments

Keywords

  • Atrial fibrillation
  • Barlow disease
  • Mitral valve repair
  • Radiofrequency ablation
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Rostagno, C., Droandi, G., Gelsomino, S., Carone, E., Gensini, G. F., & Stefàno, P. L. (2013). Surgical RF ablation of atrial fibrillation in patients undergoing mitral valve repair for barlow disease. Cardiology, 125(3), 141-145. https://doi.org/10.1159/000348565

Surgical RF ablation of atrial fibrillation in patients undergoing mitral valve repair for barlow disease. / Rostagno, Carlo; Droandi, G.; Gelsomino, S.; Carone, E.; Gensini, G. F.; Stefàno, P. L.

In: Cardiology, Vol. 125, No. 3, 06.2013, p. 141-145.

Research output: Contribution to journalArticle

Rostagno, C, Droandi, G, Gelsomino, S, Carone, E, Gensini, GF & Stefàno, PL 2013, 'Surgical RF ablation of atrial fibrillation in patients undergoing mitral valve repair for barlow disease', Cardiology, vol. 125, no. 3, pp. 141-145. https://doi.org/10.1159/000348565
Rostagno C, Droandi G, Gelsomino S, Carone E, Gensini GF, Stefàno PL. Surgical RF ablation of atrial fibrillation in patients undergoing mitral valve repair for barlow disease. Cardiology. 2013 Jun;125(3):141-145. https://doi.org/10.1159/000348565
Rostagno, Carlo ; Droandi, G. ; Gelsomino, S. ; Carone, E. ; Gensini, G. F. ; Stefàno, P. L. / Surgical RF ablation of atrial fibrillation in patients undergoing mitral valve repair for barlow disease. In: Cardiology. 2013 ; Vol. 125, No. 3. pp. 141-145.
@article{be4b80941c2843218939a93b6d4ea798,
title = "Surgical RF ablation of atrial fibrillation in patients undergoing mitral valve repair for barlow disease",
abstract = "Objectives: At present, limited experience exists on the treatment of atrial fibrillation (AF) in patients undergoing mitral valve repair (MVR) for Barlow disease. The aim of this investigation was to prospectively evaluate the radiofrequency ablation of AF in patients undergoing MVR for severe regurgitation due to Barlow disease. Methods: From January 1, 2007 to December 31, 2010, out of 85 consecutive patients with Barlow disease, 27 with AF underwent RF ablation associated with MVR. They were examined every 4 months in the first year after surgery and thereafter twice yearly. Results: At follow-up, AF was observed in 4/25 (16.0{\%}). NYHA (New York Heart Association) functional class improved significantly, with no patients in class III or IV (before surgery, 81.5{\%} had been). Otherwise, among 58 patients in sinus rhythm, 6 (11{\%}) developed AF during follow-up. No clinical or echocardiographic predictive factor was found in this subgroup. Conclusions: Results from our investigation suggest that radiofrequency ablation of AF in patients with Barlow disease undergoing MVR for severe regurgitation is effective and should be considered in every patient with Barlow disease and AF undergoing valve surgical repair.",
keywords = "Atrial fibrillation, Barlow disease, Mitral valve repair, Radiofrequency ablation, Stroke",
author = "Carlo Rostagno and G. Droandi and S. Gelsomino and E. Carone and Gensini, {G. F.} and Stef{\`a}no, {P. L.}",
year = "2013",
month = "6",
doi = "10.1159/000348565",
language = "English",
volume = "125",
pages = "141--145",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Surgical RF ablation of atrial fibrillation in patients undergoing mitral valve repair for barlow disease

AU - Rostagno, Carlo

AU - Droandi, G.

AU - Gelsomino, S.

AU - Carone, E.

AU - Gensini, G. F.

AU - Stefàno, P. L.

PY - 2013/6

Y1 - 2013/6

N2 - Objectives: At present, limited experience exists on the treatment of atrial fibrillation (AF) in patients undergoing mitral valve repair (MVR) for Barlow disease. The aim of this investigation was to prospectively evaluate the radiofrequency ablation of AF in patients undergoing MVR for severe regurgitation due to Barlow disease. Methods: From January 1, 2007 to December 31, 2010, out of 85 consecutive patients with Barlow disease, 27 with AF underwent RF ablation associated with MVR. They were examined every 4 months in the first year after surgery and thereafter twice yearly. Results: At follow-up, AF was observed in 4/25 (16.0%). NYHA (New York Heart Association) functional class improved significantly, with no patients in class III or IV (before surgery, 81.5% had been). Otherwise, among 58 patients in sinus rhythm, 6 (11%) developed AF during follow-up. No clinical or echocardiographic predictive factor was found in this subgroup. Conclusions: Results from our investigation suggest that radiofrequency ablation of AF in patients with Barlow disease undergoing MVR for severe regurgitation is effective and should be considered in every patient with Barlow disease and AF undergoing valve surgical repair.

AB - Objectives: At present, limited experience exists on the treatment of atrial fibrillation (AF) in patients undergoing mitral valve repair (MVR) for Barlow disease. The aim of this investigation was to prospectively evaluate the radiofrequency ablation of AF in patients undergoing MVR for severe regurgitation due to Barlow disease. Methods: From January 1, 2007 to December 31, 2010, out of 85 consecutive patients with Barlow disease, 27 with AF underwent RF ablation associated with MVR. They were examined every 4 months in the first year after surgery and thereafter twice yearly. Results: At follow-up, AF was observed in 4/25 (16.0%). NYHA (New York Heart Association) functional class improved significantly, with no patients in class III or IV (before surgery, 81.5% had been). Otherwise, among 58 patients in sinus rhythm, 6 (11%) developed AF during follow-up. No clinical or echocardiographic predictive factor was found in this subgroup. Conclusions: Results from our investigation suggest that radiofrequency ablation of AF in patients with Barlow disease undergoing MVR for severe regurgitation is effective and should be considered in every patient with Barlow disease and AF undergoing valve surgical repair.

KW - Atrial fibrillation

KW - Barlow disease

KW - Mitral valve repair

KW - Radiofrequency ablation

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84878348437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878348437&partnerID=8YFLogxK

U2 - 10.1159/000348565

DO - 10.1159/000348565

M3 - Article

C2 - 23736042

AN - SCOPUS:84878348437

VL - 125

SP - 141

EP - 145

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 3

ER -